
Opinion|Videos|February 20, 2025
Step Edits Associated with IV Iron Therapies
Panelists discuss how increasing insurance step edit requirements for high-dose IV iron formulations have created barriers to optimal patient care, requiring providers to implement strategic prior authorization processes and develop documentation protocols to demonstrate medical necessity while advocating for appropriate patient access to these medications.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How has the recent increase in step edits for high-dose IV iron injections impacted your practice?
- How can providers still ensure access to high-dose IV iron formulations?
Advertisement
Related to this article

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
3
Nondrug Therapies Ease Cough in Lung Cancer, Pulmonary Rehab Leads Pack
4
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
5

